While Neurocrine Biosciences (NBIX) had previously announced positive top-line Phase II data for its congenital adrenal hyperplasia (or CAH) drug crinecerfont, a fuller presentation of the trial results through the ENDO 2020 online meeting continues to support the notion that this is a worthwhile program for the company. What’s more, with relatively low expectations for usage and pricing, this could be a comparatively underappreciated asset.
Neurocrine shares have weakened a little recently, but are still up some from my last update on the company. With the crinecerfont opportunity pushing my fair value closer